Effects of Filgotinib on Semen Parameters and Sex Hormones in Male Patients with Inflammatory Diseases: Results from the Phase 2, Randomised, Double-blind, Placebo-controlled MANTA and MANTA-RAy Studies
Ann Rheum Dis 2023;82:1049–1058
Reinisch, et al. show that filgotinib treatment has no effect on semen parameters for men with active inflammatory diseases. This contrasts with pre-clinical studies that showed fertility issues in male animals.
Men with active inflammatory diseases were treated with filgotinib for 13 weeks in MANTA and MANTA-RAy. These two trials were multinational, randomised, double-blind, placebo-controlled, parallel-group, phase 2 studies.
Keywords:
